Evidence map›Paper›PMID 34208313›Full record

ArticleInternational journal of molecular sciences2021

Yurie Soejima, Miho Takeuchi, Nao Miyamoto, Motoji Sawabe, Toshio Fukusato

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yurie SoejimaDepartment of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.ORCID 0000-0002-0317-6146
Miho TakeuchiDepartment of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Nao MiyamotoDepartment of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Motoji SawabeDepartment of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.ORCID 0000-0002-7212-2547
Toshio FukusatoGeneral Medical Education and Research Center, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 178-8605, Japan.
Tokyo Medical and Dental University · JPTeikyo University · JP

Funding

Japan Society for the Promotion of Science JP19K16550Miyakawa Memorial Research Foundation None
6 · The paper itself

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a heterogeneous bile duct cancer with a poor prognosis. Integrin αvβ6 (β6) has been shown to be upregulated in iCCA and is associated with its subclassification and clinicopathological features. In the present study, two

Indexed as

Cell MovementGene Knockout TechniquesAdultAgedAged, 80 and overCalcium-Binding ProteinsCell Adhesion MoleculesCell CycleCell Line, TumorCholangiocarcinomaFemaleGene Expression Regulation, NeoplasticHumansIntegrin beta ChainsMaleMiddle AgedCalcium-Binding ProteinsCell Adhesion Moleculesintegrin beta6Integrin beta ChainsNeoplasm ProteinspodocalyxinPODXL2 protein, humanRNA, MessengerS100P protein, humanSialoglycoproteinscholangiocarcinomaCRISPR/Cas9integrinITGB6PODXL2RNA-seq

Identifiers

PMID34208313
PMCPMC8231266
OpenAlexW3166201114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.